Customize your JAMA Network experience by selecting one or more topics from the list below.
With continued community transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the US, there has been sustained focus on the role of testing to mitigate and suppress spread. After the first case of coronavirus disease 2019 (COVID-19) was diagnosed in the US in mid-January 2020, testing lagged behind due to challenges with test validation at the Centers for Disease Control and Prevention. In late February 2020, the US Food and Drug Administration (FDA) eased its restrictions on Emergency Use Authorization, which led to a rapid increase in the number of authorized tests. By May 2020, the private sector was performing 99% of US COVID-19 testing. By August 2020, the number of SARS-CoV-2 tests peaked and then plateaued at approximately 1 million tests per day. Multiple parallel efforts to bring diagnostic innovation to COVID-19 testing are underway and are likely to result in more tests as well as new innovative platforms. For instance, the Rapid Acceleration of Diagnostics program is a $1.5-billion US government program launched by the National Institutes of Health to support development, production scale-up, and deployment of rapid tests with a goal of 6 million tests available per day.1
Does the Limit of Detection Matter?
On September 15, 2020, the FDA published comparative performance data for a subset of the authorized tests against a standardized reference panel that revealed a span of test sensitivity greater than 3 log10.2 For the clinical diagnosis of patients with symptoms of COVID-19, the use of testing strategies with high sensitivity is important because a higher limit of detection could equate to missed cases of COVID-19.3 Overall, all authorized molecular tests (that amplify viral RNA) have higher sensitivity than antigen tests.
False-negative molecular testing results among hospitalized patients received substantial attention at the beginning of the pandemic, particularly for patients for whom the pretest probability was high based on clinical and radiographic findings. Given that false-negative test results occur even with the most sensitive tests due to timing during infection and sampling, diagnostic algorithms have been developed in many hospitals that include a range of clinical variables. Patients with a clinical presentation consistent with COVID-19 and an initial negative molecular test result may warrant lower respiratory tract sampling and require continued isolation. Testing alone is not enough for clinical care.
Use of Rapid, Point-of-Care Tests for Public Health vs Clinical Care
Testing in the public health setting brings different challenges. An important feature of SARS-CoV-2 is that it can be transmitted while a host is unaware of infection. Epidemiologic evidence has demonstrated that presymptomatic and asymptomatic transmission of virus has driven the current epidemic.4 High rates of household transmission—where there is often limited wearing of masks and social distancing—have been documented in a study that involved 382 children exposed to SARS-CoV-2, of whom 76% became infected.5 To limit outbreaks, testing is needed to identify as many individuals who are transmitting infection as quickly as possible so they can be isolated and their contacts can be identified and quarantined.
In this setting, the best test is not necessarily one that determines whether a person has any evidence of SARS-CoV-2, but one that quickly and accurately identifies individuals who are capable of transmitting the infection to others. However, data on the clinical and microbiologic characteristics of infectivity in both asymptomatic and symptomatic patients is limited, at least in part because upper respiratory samples must be cultured in biosafety level-3 containment laboratories. In animal models, virus culture corresponds with experimental transmission of SARS-CoV-2.6 Other measures of active virus replication include tests to identify viral subgenomic messenger RNA that is transcribed only in infected cells7 and fluorescent in situ hybridization to visualize virus together with specific cellular changes; however, neither are available as approved in vitro diagnostic tests. Despite these limited laboratory data, clinical studies suggest that the infectious period lasts from about 2 days after exposure to 12 days after symptom onset among those who develop symptomatic disease.7,8 This is also the period during which the viral load, as measured by viral RNA copies per milliliter, is likely to be highest.
Tests that can quickly identify many individuals with infectious virus (rather than simply viral RNA), including when individuals have no symptoms, could limit the spread of infection and help prevent large outbreaks. Antigen tests have the potential to serve this role. These tests capture viral proteins in a rapid lateral flow format that can be easily performed by untrained personnel and give results in less than 15 minutes. Although less sensitive than reverse transcriptase–polymerase chain reaction tests, early data suggest that antigen tests can be used to diagnose individuals with infectious virus during symptomatic COVID-19 infection.9 Antigen tests may play a key role in rapidly identifying those at highest risk for transmitting disease. However, test performance for people without symptoms is poorly understood, and more research on the value of these tests is urgently needed.
Accessibility and Acceptability of Testing at Scale
Broad use of testing requires broad acceptance of testing procedures. Nasopharyngeal swab is not conducive to frequent retesting; most patients find clinician-collected nasopharyngeal swabs invasive and uncomfortable. The use of more easily obtained specimens, such as nasal swabs (self-collected and clinician-collected), and potentially salivary sample types will be important for a broad testing strategy to work in the clinical and community settings. Access to any test continues to be challenging, particularly for individuals without adequate insurance coverage for expenses related to testing and those without easy access to testing in their communities.
In addition to understanding the performance of rapid antigen tests in the asymptomatic phase, more data are needed about how such tests could be effectively deployed in resource-limited settings. Furthermore, just as with the diagnostic setting, pretest probability remains key in interpreting the results of any test that is less than 100% sensitive and specific. The low prevalence of SARS-CoV-2 infection in most settings where testing is broadly applied, such as schools and university campuses, will lead to false-positive results and the need for secondary confirmation testing. As more tests are produced at scale, the optimized use case for each test must consider workflow (eg, number of steps, ability to be performed by paraprofessionals at point-of-care or in the home setting), turnaround time, central reporting of test results (especially positive results), and accuracy. Tests with a lower limit of detection may allow for pooling of specimens to lower the cost of screening.
Testing as Part of a Coordinated Strategy
Even as efforts continue to address these public health testing challenges, recent highly publicized outbreaks, such as university campuses and the White House, are a stark reminder that testing alone is also not sufficient to prevent community transmission. It is more accurate to consider testing less of a prevention strategy than a mitigation strategy. Testing in the absence of other proven prevention strategies is unable to prevent outbreaks.10 Even as tests become faster with higher sensitivity and specificity, social distancing, mask wearing, and avoidance of large indoor and outdoor gatherings must remain central to any public health strategy. Although the evidence is growing that widespread access to rapid antigen testing may be a pragmatic tool to interrupt the community transmission of SARS-CoV-2, what will remain equally important to prevent spread of infection to others is what happens before and after test results are delivered. Even the perfect test cannot go it alone.
Corresponding Author: Yukari C. Manabe, MD, Johns Hopkins University, 1830 E Monument St, Room 443, Baltimore, MD 21287 (firstname.lastname@example.org).
Published Online: November 13, 2020. doi:10.1001/jama.2020.21694
Conflict of Interest Disclosures: Dr Manabe reported receiving grants from Becton-Dickinson, Hologic, Quanterix, and miDiagnostics outside the submitted work. No other disclosures were reported.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Manabe YC, Sharfstein JS, Armstrong K. The Need for More and Better Testing for COVID-19. JAMA. 2020;324(21):2153–2154. doi:10.1001/jama.2020.21694
Create a personal account or sign in to: